Compare · MESO vs RVMD
MESO vs RVMD
Side-by-side comparison of Mesoblast Limited (MESO) and Revolution Medicines Inc. (RVMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MESO and RVMD operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- RVMD is the larger of the two at $41.57B, about 22.4x MESO ($1.86B).
- Over the past year, MESO is down 22.0% and RVMD is up 296.4% - RVMD leads by 318.4 points.
- RVMD has been more active in the news (10 items in the past 4 weeks vs 3 for MESO).
- RVMD has more recent analyst coverage (25 ratings vs 14 for MESO).
- Company
- Mesoblast Limited
- Revolution Medicines Inc.
- Price
- $13.90-2.80%
- $188.40-2.89%
- Market cap
- $1.86B
- $41.57B
- 1M return
- -7.49%
- -8.12%
- 1Y return
- -22.04%
- +296.37%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2015
- 2020
- News (4w)
- 3
- 10
- Recent ratings
- 14
- 25
Mesoblast Limited
Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage adult stem cells. The company's products under the Phase III clinical trials include MSC-100-IV for steroid refractory acute graft versus host disease; MPC-150-IM for advanced heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV that is in Phase II clinical trials for the treatment of biologic refractory rheumatoid arthritis, diabetic kidney diseases, and type 2 diabetic nephropathy. It operates in the United States, Australia, Singapore, the United Kingdom, and Switzerland. Mesoblast Limited has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. for the treatment of wound healing in patients with epidermolysis bullosa; and Grünenthal to develop and commercialize cell therapy for the treatment of chronic low back pain. The company was founded in 2004 and is headquartered in Melbourne, Australia.
Revolution Medicines Inc.
Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). Revolution Medicines, Inc. has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. The company was incorporated in 2014 and is headquartered in Redwood City, California.
Latest MESO
- SEC Form 6-K filed by Mesoblast Limited
- Mesoblast Receives FDA Approval for New Potency Assay to Release Commercial Ryoncil Product
- SEC Form 6-K filed by Mesoblast Limited
- SEC Form 6-K filed by Mesoblast Limited
- SEC Form 20-F filed by Mesoblast Limited
- Mesoblast Reports Substantial Revenue Growth to US$120M
- SEC Form 6-K filed by Mesoblast Limited
- SEC Form 6-K filed by Mesoblast Limited
- Mesoblast Financial Results and Corporate Update Webcast
- Mesoblast Achieves Major Milestone Completing Patient Treatment in Pivotal Phase 3 Trial for Chronic Low Back Pain
Latest RVMD
- Cancer Drug Spending Is Headed Past $400 Billion as Colorectal and Pancreatic Cancers Move Up the Research Agenda
- SEC Form 8-K filed by Revolution Medicines Inc.
- Revolution Medicines Begins Treating Patients in Phase 3 RASolute 309 Trial Evaluating RASONQUE™ (daraxonrasib) Plus Zoldonrasib as First-Line Treatment for Metastatic RAS G12D Pancreatic Cancer
- Chief Development Officer Sandler Alan B. exercised 6,000 shares at a strike of $58.84 and sold $1,275,294 worth of shares (6,309 units at $202.14) as part of a pre-agreed trading plan, decreasing direct ownership by 0.58% to 52,559 units (SEC Form 4)
- SVP & General Counsel Cislini Jeff sold $158,600 worth of shares (765 units at $207.32) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 51,776 units (SEC Form 4)
- Officer Mancini Anthony sold $743,285 worth of shares (3,708 units at $200.45) as part of a pre-agreed trading plan and exercised 3,121 shares at a strike of $33.62, decreasing direct ownership by 1% to 39,765 units (SEC Form 4)
- KRAS Inhibitor Market Projected to Reach $7.8 Billion by 2034
- Director Anderson Elizabeth M exercised 5,070 shares at a strike of $1.12 and sold $1,958,016 worth of shares (10,143 units at $193.04) as part of a pre-agreed trading plan, decreasing direct ownership by 54% to 4,333 units (SEC Form 4)
- Goldman resumed coverage on Revolution Medicines with a new price target
- Officer Mancini Anthony sold $347,402 worth of shares (1,764 units at $196.94) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 40,352 units (SEC Form 4)